PharmaShots | Incisive News in 3 Shots

Subscribe Now

Unresectable Hepatocellular Carcinoma

Roche's Tecentriq in Combination with Avastin Receives China NMPA's Approval for the Treatment of Unresectable Hepatocellular Carcinoma

Roche's Tecentriq in Combination with Avastin Receives China NMPA's Approval for the Treatment of Unresectable Hepatocellular Carc...

October 30, 2020

Chugai's Tecentriq (atezolizumab) and Avastin (bevacizumab) Receive MHLW's Approval as 1L Treatment for Unresectable Hepatocellular Carcinoma

Chugai's Tecentriq (atezolizumab) and Avastin (bevacizumab) Receive MHLW's Approval as 1L Treatment for Unresectable Hepatocellula...

September 28, 2020

Roche Reports Results of Tecentriq (atezolizumab) + Avastin (bevacizumab) in P-III IMbrave150 for Unresectable Hepatocellular Carcinoma at ESMO Congress 2019

Roche Reports Results of Tecentriq (atezolizumab) + Avastin (bevacizumab) in P-III IMbrave150 for Unresectable Hepatocellular Carc...

November 25, 2019

Roche Reports Result of Tecentriq (atezolizumab) + Avastin (bevacizumab) in P-III IMbrave150 Study for Unresectable Hepatocellular Carcinoma

Roche Reports Result of Tecentriq (atezolizumab) + Avastin (bevacizumab) in P-III IMbrave150 Study for Unresectable Hepatocellular...

October 21, 2019

Eisai and Merck Annouces the US FDA Approval of Lenvima for Unresectable 1L Hepatocellular Carcinoma (HCC)

Eisai and Merck Annouces the US FDA Approval of Lenvima for Unresectable 1L Hepatocellular Carcinoma (HCC)

August 17, 2018

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us